ProfileGDS5678 / 1449213_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 88% 87% 88% 90% 90% 89% 91% 89% 89% 88% 89% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7206688
GSM967853U87-EV human glioblastoma xenograft - Control 26.9858188
GSM967854U87-EV human glioblastoma xenograft - Control 36.8309488
GSM967855U87-EV human glioblastoma xenograft - Control 46.9093187
GSM967856U87-EV human glioblastoma xenograft - Control 56.964888
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9797690
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.967590
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0017789
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.391391
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9887889
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9697989
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8949588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0580289
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1581490